Risk-Adjusted NPV (rNPV)

A valuation method that discounts projected cash flows by both the time value of money (WACC) and the probability of success at each development phase. rNPV accounts for clinical and regulatory risk by applying phase-specific probability-of-success rates to future revenue streams, making it the standard valuation approach for biopharma licensing and M&A transactions.